CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's Lymphoma.
Xue Y, Lai X, Li R, Ge C, Zeng B, Li Z, Fu Q, Zhao L, Dong S, Yang J, Guo J, Meng Q, Tan Q, Li Z, Ding H, Zhang Y, Liu S, Chang AH, Yao H, Luo R.
Xue Y, et al. Among authors: tan q.
Front Oncol. 2021 Feb 2;10:607362. doi: 10.3389/fonc.2020.607362. eCollection 2020.
Front Oncol. 2021.
PMID: 33604290
Free PMC article.